HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, Oct. 30, 2017 (HealthDay News) -- Automated breast ultrasonography may not be of added value to yearly full-field digital (FFD) mammography and dynamic contrast agent-enhanced (DCE) magnetic resonance (MR) imaging surveillance of carriers of the BRCA mutation, according to a study published in the November issue of Radiology.
Jan C.M. van Zelst, M.D., from Radboud University Medical Centre in the Netherlands, and colleagues prospectively followed 296 carriers of the BRCA mutation (153 BRCA1 and 128 BRCA2 carriers, plus 15 women with first-degree untested relatives) using two years of intensified surveillance including biannual automated breast ultrasound as well as routine yearly DCE MR imaging and FFD mammography.
The researchers found that breast cancer was screening-detected in 16 women. Sensitivity of DCE MR imaging, FFD mammography, and automated breast ultrasound was 68.1 percent, 37.2 percent, and 32.1 percent, respectively, while specificity was 95 percent, 98.1 percent, and 95.1 percent, respectively. For the three modalities, the cancer detection rate was 2, 1.2 percent, and 1 percent per 100 women-years, while positive predictive value was 25.2 percent, 33.7 percent, and 9.5 percent. The highest sensitivity -- 76.3 percent -- was seen with the combination of DCE MR imaging and FFD mammography, which had a specificity of 93.6 percent. Automated breast ultrasound depicted no additional cancers, and FFD mammography did not yield additional cancers in women younger than 43 years, the mean age at diagnosis.
"Study results suggest that carriers of the BRCA mutation younger than 40 years may not benefit from FFD mammography surveillance in addition to DCE MR imaging," conclude the authors.
Two authors disclosed financial ties to the medical device and imaging industries.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 29, 2022